 Prime Medicine Inc. PRME, has set terms for its initial public offering, in which the Massachusetts-based biotechnology company, which utilizes gene-editing technology to develop therapies for a wide spectrum of diseases, looks to raise up 160.2 million. The company said it is offering 8.9 million shares in the IPO, which is expected to priced between 16 and 18 a share. 